References
- Beutler E. Nutritional and metabolic aspects of glutathione. Annu Res Nutr 1989; 9: 287–302
- Glutathione cented. Molecular pro-specfives and clinical implications, N Taniguchi, T Higashi, Y Sakamoto, A Meister. Academic Press, San Diego, California 1989
- Loguercio C, Del Veochio Blanco C, Coltorti M, Nardi G. Alteration of erythrocyte glutathione, cysteine and glutathione-synthetase in alcoholic and non-alcoholic cirrhosis. Scand J Clin Lab Invest 1992; 52: 207–13
- Altomare E, Vendemiale G, Palasciano G, Portincasa P, Albano O. Decrease of hepatic glutathione levels during non-alcoholic liver injury. Patho-physiology of the liver, P Gentilini, MU Dianzam. Elsevier, 131–7
- Burgunder JM, Lauterburg BH. Decreased production of glutathione in patients with cirrhosis. Eur J Clin Invest 1987; 17: 1988, 408–14
- Shaw S. Lipid peroxidation, iron mobilization and free radical generation induced by alcohol. Free Rad Biol Med 1989; 7: 541–7
- Shaw S, Rubin KP, Lieber CS. Depressed hepatic glutathione and increased diene conjugates in alcoholic liver disease. Evidence of lipid peroxidation. Dig Dis Sci 1983; 28: 585–91
- Loguerao C, Clot P, Petrone E, Arico' S, Argenzio F. Lipid peroxidation and glutathione depletion in the erythrocyta of chronic alcohol abusers. Ital J Gastroenterol 1993; 5: 113
- Lieber CS. Metabolism and metabolic effects of ethanol. Semin Liver Disease 1981; 1: 188–202
- Csomós G, Feher J. Free radicals and the liver. Springer Verlag, Berlin 1992
- Meister A. Function of glutathione, Larson. Raven Press, New York, 1–22
- Poulsen HE, Loft S. Antipyrine as a model drug to study hepatic metabolizing capacity. J Hepatol 1988; 6: 1983, 374–82
- Tygstrup N. Determination of the hepatic elimination liver mass of galactose by single injection. Scand J Clin Lab Invest 1966; 18: 118–25
- Branch RA, Herbert CM, Read AE. Determinants of serum antipyrine half-lives in patients with liver dim. Gut 1973; 14: 569–73
- Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagous for bleeding of oesophageal varies. Br J Surg 1973; 60: 646–8
- Marchesini G, Bua V, Brunori A, Bianchi F, Pisi E, Fabbri A, et al. Galactose elimination capacity and liver volume in aging man. Gastroenterology 1988; 8: 1079–83
- Keidmg S. Galactose clearance measurement and liver blood flow. Gastroenterology 1988; 94: 477–81
- Andreasen P, Ranek BE, Tygstrup N. Clearance of antipyrine dependence of quantitative liver function. Eur J Clin Invest 1974; 4: 129–34
- Udupi V, Rice-Evans C. Thiol compounds as protective agents in erythrocytes under oxidative stress. Free Rad Res Comm 1992; 16: 3125–3
- Loguercio C, Audio R, Petrone E, Paura A, Argenzio F, Grella A, et al. Effects of glutathione treatment on psychometric tests in chronic alcoholics. Alcologia 1993; 5: 237–41
- Ceccanti M, Virgili F, Balducci G, Romeo M, Santini P. Effect of reduced glutathione administration on serum indices of oxidative stress after cessation of chronic alcohol abuse. Alcologia 1994; 6(1)33–8
- Shimizu M, Morita S. Effects of feeding and fasting on hepatolobular distribution of glutathione and cadmium-induced hepatotoxicity. Toxicology 1992; 75: 97–107
- Lauterburg BH, Velez ME. Glutathione deficiency in alcoholics: risk factor for paracetamol hepatotoxicity. Gut 1988; 29: 1153–7
- Beloqui O, Pristo I, Suarez M, Gil B, Qian CH, Garcia N, et al. N-acetyl-cysteine enhances the response to interferon alpha in chronic hepatitis C: a pilot study. J Interferon Res 1993; 13: 279–82
- Bardellini E, Bindi P, Borzone S, Caglieri S, Dagnino F, Testa R. The effect of high doses of reduced glutathione on hepatic clearances and fib-rogenetic activity in patients with chronic alcoholic liver disease. Adv Ther 1992; 9: 116–22
- Ayala F, Budillon G, Monfregola G, Santoianni P. Plasma antipyrine half-life in prophyria cutanea tarda. Ann Ital Derm Clin Sper 1984; 38: 369–75
- Kawasaki S, Imamura H, Kokudo N, Bandai Y, Sanjo K, Idezuki Y. A comparison between antipyrine and aminopyrine blood clearances. Hepato-Gastroenterology 1992; 39(4)344–6
- Vestal RE, Norris AH, Tobin JD, Cohen BH, Schock NW, Andres R. Antipyrine metabolism in man: influence of age, alcohol, caffeine and smoking. Clin Pharmacol Ther 1975; 18: 425–32
- Tsyrkunov VM, Bushma MI, Garelik PV, Novitskii GH, Zavodnik LB. Pharmacokinetics of antipyrine in viral and alcoholic lesion of the liver. Klin Med (Moscow) 1989; 76: 87–9
- Wolff TH, Strecker M. Endogenous and exogenous factors modifying the activity of human liver cytocrome P450 enzymes. Exp Toxicol Pathol 1999; 44: 263–271
- Ingelman-Sundberg M, Jornvall H. Induction of the ethanol-inducible form of rabbit liver micro-somal cytochrome P-450 by inhibitors of alcohol-dehydrogenase. Biochim Biophys Acta 1984; 124: 375–82
- Ekstrom G, Cronholm T, Lngelman-Sundbexg M. Hydroxil-radical production and ethanol oxidation by liver microsomes isolated from ethanol-treated rats. Biochem J 1986; 233: 755–61
- Nordmann R, Ribikre C, Rouach H. Implication of free radical mechanisms in ethanol-induced cellular injury. Free Rad Biol Med 1992; 12: 219–40
- Upreti KK, Das M, Khanna SK. Biochemical toxycology of argemone oil. Effect on hepatic cytochrome P-450 and xenobiotic metabolizing enzymes. J Appl Toxicol 1991; 11: 203–9
- Seitz HK, Simanowski UA. Aging, alcoholism and alcohol-drug interaction. Alcologia 1994; 6(2)81–7
- Kramer RA. Cytochrome P-450-dependent formation of alkylating metabolites in the chloroethylni-trosoureas MeCCNU and CCNU. Biochem Pharmacol 1989; 38: 3185–92
- Jurima-Romet M, Huang HS. Enalapril hepatotoxicity in the rat: effects of modulators of cytochrome P-450 and glutathione. Biochem Pharmacol 1992; 44: 803–10
- Decker CJ, Doerge DR. Rat hepatic microsomal metabolism of ethylenthiourea. Contributions of the flavin-containing monooxygenase and cytochrome P-450 isoenzymes. Chem Res Toxicol 1991; 4: 482–9
- Natsuhori M, Witkamp RF, Van't KJoster GAE, Van Miert AS. Metabolism of antipyrine and sul-phadimidine in dwarf goats: effects of the enzyme-inducing agents phenobarbital, troleandomycin and rifampicin. Xenobiotica 1992; 11: 1243–50
- Callaghan R, Desmond PV, Paull P, Mashford ML. Hepatic enzyme activity is the major factor determining elimination rate of high-clearance drugs in cirrhotics. Hepatology 1993; 1: 54–60
- Lidell DE, Williams FM, Briant RH. Phenazone (antipyrine) metabolism and distribution in young and elderly adults. Clin Exper Pharmacol Physiol 1975; 2: 481–7